Medanta Q1 FY27 revenue up 22%, PAT dips 10%

Revenue Growth 20pctExceptional ItemResults View source PDF Explain this filing

MEDANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹1423.00

prior close

₹1390.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.5%-1.0% vs market

Hospital peers, median of 25sector-0.3%-0.3% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Midcap 150 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

-2.2

15m

-1.6

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.5-1.0-0.3-0.3

Next day

+1.9+1.7+0.2-0.0+1.9

+0.8+1.4-0.5-0.4+1.2

-1.1+1.6-2.8-0.5-0.6

+2.1+1.2+0.9+0.3+1.8

+2.7+1.4+1.3+1.0+1.7

+1.2+1.9-0.7+0.5+0.7

15d

-0.6+1.6-2.3-3.2+2.6

+4.6+2.2+2.4-4.3+8.9

-3.9-5.1+1.1-7.2+3.3

—————

UpDownMarket · Nifty Midcap 150Sector · Hospital peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medanta Q1 FY27 standalone revenue rose 22.3% YoY to Rs 1,079 cr (consolidated up 26.5% at Rs 1,304 cr). Standalone PAT fell 9.6% to Rs 137 cr due to higher employee and finance costs. Final dividend of Rs 0.50 per share declared with record date Aug 14. Board approved revised Guwahati hospital plan raising capacity from 400 to 650 beds at about Rs 970 cr over 3-4 years. Also signed a deal to acquire a 79-bed oncology hospital in Indore.

Likely market impact

Strong topline growth but margin pressure from higher staff and finance costs. Aggressive expansion and acquisition signal long-term growth push.